Stoltzfus R, Dreyfuss M. Guidelines for the use of iron supplements to prevent and treat iron deficiency anemia. Gr: Int. Nutr. Anemia Consult; 1998.
Zimmermann MB, Hurrell RF, CDC, et al. Nutritional iron deficiency. Lancet (London, England) 2007;370(9586):511–20.
Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–95.
Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009;25(2):122–8.
McLean E, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–54.
Lundström U. Iron deficiency anaemia. Gut. 1994;35(6):864–5.
Anon. World Health Organization, UNICEF, UNU. Iron Deficiency Anaemia Assessment, Prevention and Control: a Guide for Programme Managers. Geneva: World Health Organization, 2001. http://apps.who.int/iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf. Accessed 21 Dec 2016.
Hegde N, Rich MW, Gayomali C. The cardiomyopathy of iron deficiency. Texas Hear Inst J. 2006;33(3):340–4.
Gurusamy KS, Nagendran M, Broadhurst JF, et al. Iron therapy in anaemic adults without chronic kidney disease. Cochrane Database Syst. Rev. 2014;(12):CD010640.
Albaramki J, Hodson EM, Craig JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 2012;1:CD007857.
Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39(2):130–41.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–68.
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48.
Okonko DO, Mandal AKJ, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241–51.
Jankowska EA, Von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816–26.
Evstatiev R, Bukaty A, Jimenez K, et al. Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol. 2014;89(5):524–9.
Bonaccorsi-Riani E, Danger R, Lozano JJ, et al. Iron deficiency impairs intra-hepatic lymphocyte mediated immune response. PLoS One. 2015;10(8):e0136106.
Attia MA, Essa SA, Nosair NA, et al. Effect of iron deficiency anemia and its treatment on cell mediated immunity. Indian J Hematol Blood Transfus. 2009;25(2):70–7.
Hughes CM, Woodside JV, McGartland C, et al. Nutritional intake and oxidative stress in chronic heart failure. Nutr Metab Cardiovasc Dis. 2012;22(4):376–82.
Lourenço BH, Vieira LP, Macedo A, et al. Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. Arq Bras Cardiol. 2009;93(5):541–8.
Hallberg L, Hulthén L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr. 2000;71(5):1147–60.
González-Costello J, Comín-Colet J. Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail. 2010;12(11):1159–62.
Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am. Heart J. 2013;165(4):575–582.e3.
Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–80.
Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827–34.
Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468–76.
Moreno Chulilla JA, Romero Colás MS, Gutiérrez Martín M. Classification of anemia for gastroenterologists. World J Gastroenterol. 2009;15(37):4627–37.
Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–16.
Gale E, Torrance J, Bothwell T. The quantitative estimation of total iron stores in human bone marrow. J. Clin. Invest. 1963;42(7):1076–82.
Pasricha S-RS, Flecknoe-Brown SC, Allen KJ, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust. 2010;193(9):525–32.
Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–61.
Koulaouzidis A, Said E, Cottier R, et al. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis. 2009;18(3):345–52.
Ali MA, Luxton AW, Walker WH. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J. 1978;118(8):945–6.
WHO. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. In: WHO.; 2011:1–5.
Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol. 2011;64(4):281–6.
Zhang A-S, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology. 2009;2009(1):207–14.
Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24–38.
Anderson GJ, Frazer DM, McLaren GD. Iron absorption and metabolism. Curr. Opin. Gastroenterol. 2009;25(2):129–35.
Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009;66(20):3241–61.
Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011;434(3):365–81.
Koorts AM, Viljoen M. Ferritin and ferritin isoforms I: structure–function relationships, synthesis, degradation and secretion. Arch Physiol Biochem. 2007;113(1):30–54.
Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Supplement 1):S4–8.
Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009;11(11):1084–91.
Skikne BS. Serum transferrin receptor. Am J Hematol. 2008;83(11):872–5.
Parikh A, Natarajan S, Lipsitz SR, et al. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Hear Fail. 2011;4(5):599–606.
Comín-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15(10):1164–72.
Kasner M, Aleksandrov AS, Westermann D, et al. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Int J Cardiol. 2013;168(5):4652–7.
Rangel I, Gonçalves A, de Sousa C, et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014;128(4):320–6.
Yeo TJ, Yeo PSD, Ching-Chiew Wong R, et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014;16(10):1125–32.
Schou M, Bosselmann H, Gaborit F, et al. Iron deficiency: prevalence and relation to cardiovascular biomarkers in heart failure outpatients. Int J Cardiol. 2015;195:143–8.
Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol. 2016;205:6–12.
Núñez J, Domínguez E, Ramón JM, et al. Iron deficiency and functional capacity in patients with advanced heart failure with preserved ejection fraction. Int J Cardiol. 2016;207:365–7.
Enjuanes C, Bruguera J, Grau M, et al. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. Rev. Esp. Cardiol. (Engl. Ed). 2016;69(3):247–55.
Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485–9.
Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16(9):984–91.
de Silva R, Rigby AS, Witte KK a, et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98(3):391–8.
Belmar Vega L, Francisco A de, Albines Fiestas Z, et al. Iron deficiency in patients with congestive heart failure: a medical practice that requires greater attention. Nefrol. (English Ed.) 2016;36(3):249–254.
Przybylowski P, Wasilewski G, Golabek K, et al. Absolute and functional iron deficiency is a common finding in patients with heart failure and after heart transplantation. Transpl Proc. 2016;48(1):173–6.
Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J. Card. Fail. 2011;17(11):899–906.
Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174(2):268–75.
Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18(7):798–802.
Hallberg L, Hulthén L, Garby L. Iron stores in man in relation to diet and iron requirements. Eur J Clin Nutr. 1998;52(9):623–31.
Collings R, Harvey LJ, Hooper L, et al. The absorption of iron from whole diets: a systematic review. Am J Clin Nutr. 2013;98(1):65–81.
Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Ther Adv Gastroenterol. 2011;4(3):177–84.
Harrington M, Hotz C, Zeder C, et al. A comparison of the bioavailability of ferrous fumarate and ferrous sulfate in non-anemic Mexican women and children consuming a sweetened maize and milk drink. Eur J Clin Nutr. 2011;65(1):20–5.
Navas-Carretero S, Sarriá B, Pérez-Granados AM, et al. A comparative study of iron bioavailability from cocoa supplemented with ferric pyrophosphate or ferrous fumarate in rats. Ann Nutr Metab. 2007;51(3):204–7.
Lysionek AE, Zubillaga MB, Salgueiro MJ, et al. Stabilized ferrous gluconate as iron source for food fortification: bioavailability and toxicity studies in rats. Biol Trace Elem Res. 2003;94(1):73–8.
Brise H, Hallberg L. Absorbability of different iron compounds. Acta Med Scand Suppl. 1962;376:23–37.
Anon. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Repo Morb Mortal Wkly Report Recomm Rep. 1998;47(RR-3):1–29.
Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Sci World J. 2012;2012:1–5.
Coe EM, Bowen LH, Speer JA, et al. The recharacterization of a polysaccharide iron complex (Niferex). J Inorg Biochem. 1995;58(4):269–78.
Coe EM, Bowen LH, Speer JA, et al. Comparison of polysaccharide iron complexes used as iron supplements. J Inorg Biochem. 1995;57(4):287–92.
Klein-Schwartz W. Toxicity of polysaccharide-iron complex exposures reported to poison control centers. Ann Pharmacother. 2000;34(2):165–9.
Liu T-C, Lin S-F, Chang C-S, et al. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study. Int J Hematol. 2004;80(5):416–20.
Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981–9.
Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10):1142–7.
Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075–84.
Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846–56.
Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55–62.
Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445–54.
Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170–4.
Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19(8):1599–605.
Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transpl. 2001;16(5):967–74.
Niehaus ED, Malhotra R, Cocca-Spofford D, et al. Repletion of iron stores with the use of oral iron supplementation in patients with systolic heart failure. J Card Fail. 2015;21(8):694–7.
Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152(6):1096.e9–1096.e15.
Lewis GD, Semigran MJ, Givertz MM, et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail. 2016;9(5):e000345.
Lewis GD et al. Oral iron repletion effects on oxygen uptake in heart failure (IRONOUT). Presented at: American Heart Association Scientific Sessions 2016. November 15, 2016. New Orleans, LA.
Heath CW, Strauss MB, Castle WB. Quantitative aspects of iron deficiency in hypochromic anemia: (the parenteral administration of iron). J Clin Invest. 1932;11(6):1293–312.
Goetsch AT, Moore CV, Minnich V. Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. J Lab Clin Med. 1946;31:466.
Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. JBIC J Biol Inorg Chem. 2007;13(1):57–74.
Silvestri L. Inhibiting the hepcidin inhibitor for treatment of iron overload. Blood. 2013;121(7):1068–9.
Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care. 2009;35(Suppl 2):8–13.
Robles-Mezcua A, González-Cruces N, Ruiz-Salas A, et al. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction. Int J Cardiol. 2016;202:118–20.
Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1225–7.
Toblli JE, Lombraña A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657–65.
Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51(2):103–12.
Usmanov RI, Zueva EB, Silverberg DS, et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21(2):236–42.
Terrovitis JV, Kaldara E, Ntalianis A, et al. Intravenous iron alone is equally effective with the combination of iron and erythropoietin for the treatment of iron-deficiency anemia in advanced heart failure. J Am Coll Cardiol. 2012;60(21):2255–6.
Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439–42.
Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Hear Lung Circ. 2015;24(7):686–95.
Gaber R, Kotb NA, Ghazy M, et al. Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography. 2012;29(1):13–8.
Kaminsky BM, Pogue KT, Hanigan S, et al. Effects of total dose infusion of iron intravenously in patients with acute heart failure and anemia (hemoglobin <13 g/dl). Am J Cardiol. 2016;117(12):1942–6.
Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11(4):131–7.
Reed BN, Blair EA, Thudium EM, et al. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency. Pharmacotherapy. 2015;35(1):64–71.
Anon. Dexferrum - Summary of Product Characteristics. https://www.drugs.com/cdi/dexferrum.html. Accessed 9 July 2016.
Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep’s clothing? J Am Soc Nephrol. 2008;19(5):833–4.
Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101:67–73.
Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am. J. Obstet. Gynecol. 2008;199(4):435.e1–435.e7.
Dhanani JV, Ganguly BP, Chauhan LN. Comparison of efficacy and safety of two parenteral iron preparations in pregnant women. J Pharmacol Pharmacother. 2012;3:314–9.
Anon. Ferric carboxymaltose - Summary of Product Characteristics. https://www.drugs.com/ppa/ferric-carboxymaltose.html. Accessed 21 Dec 2016.
Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) Randomized Controlled Trial. Am J Gastroenterol. 2008;103(5):1182–92.
Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100(7):301–3.
Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail. 2013;15(11):1267–76.
Kalra PA, Bock K, Meldal M. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port J Nephrol Hypertens. 2012;26(1):13–24.
Anon. Infed—Summary of Product Characteristics. https://www.drugs.com/mtm/infed.html. Accessed 9 July 2016.
Anon. Cosmofer—Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/14139. Accessed 9 July 2016.
Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76(1):74–8.
Beshara S, Lundqvist H, Sundin J, et al. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol. 1999;104(2):296–302.
Danielson BG, Salmonson T, Derendorf H, et al. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996;46(6):615–21.
Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration. Am J Kidney Dis. 2003;41(3):651–7.
Anon. Ferumoxytol—Summary of Product Characteristics. http://www.rxlist.com/feraheme-drug.htm. Accessed 11 Nov 2016.
Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–15.
Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1):12–33.
Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):386–93.
Anon. Ferrosig (iron polymaltose) Australian approved product information. Rowville: Sigma Co. Ltd. Accessed online via MIMS Online 14 August 2013. Approved 08.04.2002, amended 06.05.2015.
Haines ML, Gibson PR. Delayed adverse reactions to total-dose intravenous iron polymaltose. Intern. Med. J. 2009;39(4):252–5.
Anon. Iron sorbitol Summary of Product Characteristics. https://www.drugs.com/mmx/iron-sorbitol.html. Accessed 21 Dec 2016.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Hear Fail. 2014;1(1):52–8.
Kapoor M, Schleinitz MD, Gemignani A, et al. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord Drug Targ. 2013;13(1):35–44.
Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012;14(4):423–9.
Desai A, Lewis E, Solomon S, et al. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010;12(9):936–42.
Qian C, Wei B, Ding J, et al. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Can J Cardiol. 2016;32(2):151–9.
Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786–95.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975.
Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6a):362–72.
Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25(4):400–10.